ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

emicizumab

Its studies are mostly in Hemophilia A, led by 2 companies.

Drug pageEmicizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 20, 201713 company-led studies, 4 open or runningNext primary completion: Nov 19, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only123 open or runningphase 4since Nov 20, 2017Dec 2, 2015Nov 19, 2026phase 4 · NCT05181618
Sanofiits history only11 open or runningphase 4since Nov 17, 2023Nov 17, 2023May 28, 2028phase 4 · NCT06145373

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named emicizumabINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Dec 2, 2015First study: phase 3 study in Hemophilia ANew to Hoffmann-La RocheHoffmann-La Roche · NCT02622321 · 113 enrolled · United States, Australia, Costa Rica and more
  3. Jun 7, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02795767 · 88 enrolled · United States, Costa Rica, France and more
  4. Jul 26, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT02847637 · 152 enrolled · United States, Australia, Costa Rica and more
  5. Dec 21, 2016Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03020160 · 48 enrolled · United States, Australia, Belgium and more
  6. Jun 15, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03191799 · 195 enrolled · Australia, Belgium, Brazil and more
  7. Oct 17, 2017Phase 3 study in Hemophilia AHoffmann-La Roche · NCT03315455 · 85 enrolled · China, Hong Kong, Malaysia and more
  8. Nov 20, 2017Phase 4 study in Hemophilia AHoffmann-La Roche · NCT03361137 · 14 enrolled · United States
  9. Dec 13, 2017Phase 1 study in Hemophilia AHoffmann-La Roche · NCT03380780 · 16 enrolled · China
  10. Nov 7, 2019Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04158648 · 73 enrolled · United States, Belgium, Canada and more
  11. Jun 11, 2020Phase 3 study in Hemophilia AHoffmann-La Roche · NCT04431726 · 55 enrolled · United States, Australia, Austria and more
  12. Dec 6, 2021Phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618 · 136 enrolled · United States, Brazil, Canada and more
  13. Nov 17, 2023Sanofi’s first study: phase 4 study in Hemophilia ANew to SanofiSanofi · NCT06145373 · 20 planned · United States, Taiwan
  14. May 22, 2025Phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524 · 75 planned · United States, Belgium, Canada and more
  15. Nov 16, 2026Primary completion moved from 2027-04-30 to 2027-10-06Date moved laterphase 3 · +5 months · NCT06998524

Ahead

  1. Nov 19, 2026Primary completion: phase 4 study in Hemophilia AHoffmann-La Roche · NCT05181618
  2. Oct 6, 2027Primary completion: phase 3 study in von Willebrand Disease, Type 3Hoffmann-La Roche · NCT06998524
  3. May 28, 2028Primary completion: phase 4 study in Hemophilia ASanofi · NCT06145373

TargetBeta

F10 →F9 →read by rule
“Coagulation factor IX and X other”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06998524von Willebrand Disease, Type 3 · United States, Belgium, Canada and more3RecruitingHoffmann-La RocheOct 6, 202775
NCT06145373Hemophilia A · United States, Taiwan4RecruitingSanofiMay 28, 202820
NCT05181618Hemophilia A · United States, Brazil, Canada and more4Active, not recruitingHoffmann-La RocheNov 19, 2026136
NCT04431726Hemophilia A · United States, Australia, Austria and more3Active, not recruitingHoffmann-La RocheMay 22, 202355
NCT04158648Hemophilia A · United States, Belgium, Canada and more3CompletedHoffmann-La RocheOct 30, 202173
NCT03380780Hemophilia A · China1CompletedHoffmann-La RocheSep 18, 201816
NCT03361137Hemophilia A · United States4TerminatedHoffmann-La RocheMar 13, 202014
NCT03315455Hemophilia A · China, Hong Kong, Malaysia and more3CompletedHoffmann-La RocheAug 3, 202285
NCT03191799Hemophilia A · Australia, Belgium, Brazil and more3CompletedHoffmann-La RocheNov 19, 2020195
NCT03020160Hemophilia A · United States, Australia, Belgium and more3CompletedHoffmann-La RocheDec 15, 201748
NCT02847637Hemophilia A · United States, Australia, Costa Rica and more3CompletedHoffmann-La RocheSep 15, 2017152
NCT02795767Hemophilia A · United States, Costa Rica, France and more3CompletedHoffmann-La RocheApr 30, 201888
NCT02622321Hemophilia A · United States, Australia, Costa Rica and more3CompletedHoffmann-La RocheOct 25, 2016113

How it is read

Names in the registry

  • “Emicizumab”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.